A Randomised Single-Blind Controlled Trial Comparing Efficacy of Intralesional Vitamin D Injection and MMR (Measles, Mumps, Rubella) Vaccine in Treatment of Warts.

IF 1 4区 医学 Q4 DERMATOLOGY
Indian Journal of Dermatology Pub Date : 2025-05-01 Epub Date: 2025-05-08 DOI:10.4103/ijd.ijd_890_23
Sushil Singh, Shrayan Pal, Abhishek De
{"title":"A Randomised Single-Blind Controlled Trial Comparing Efficacy of Intralesional Vitamin D Injection and MMR (Measles, Mumps, Rubella) Vaccine in Treatment of Warts.","authors":"Sushil Singh, Shrayan Pal, Abhishek De","doi":"10.4103/ijd.ijd_890_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Common warts are benign skin lesions caused by human papillomavirus (HPV) infection. They are often resistant to conventional treatments and may cause cosmetic and psychological distress. Immunotherapy is a promising alternative that stimulates the host immune system to clear the virus and the infected cells. This study compared the efficacy and safety of two immunotherapeutic agents, intralesional measles, mumps, and rubella (MMR) vaccine and intralesional vitamin D, in the treatment of common warts.</p><p><strong>Methods: </strong>This was a single-blind randomised controlled trial conducted at a tertiary care hospital in Kolkata, India. Patients aged 12 years or older with common warts were randomly assigned to receive either intralesional MMR vaccine or intralesional vitamin D every 3 weeks for a maximum of three doses or until complete resolution, whichever was earlier. The primary outcome was the reduction in the size of the largest wart. Secondary outcomes included patients' and physicians' global assessment, complete response rate, adverse effects, and recurrence rate.</p><p><strong>Results: </strong>A total of 36 patients were enrolled and analysed. Both MMR and vitamin D groups showed a significant reduction in the size of the largest wart throughout the treatment period (<i>P</i> < 0.0001). There was no significant difference between the two groups in terms of size reduction, patients' and physicians' global assessment and adverse effects. The complete response rate was higher in the MMR group (64.7%) than in the vitamin D group (36.8%); however, the difference was not statistically significant (<i>P</i> = 0.14). The recurrence rate was low in both groups (5.9% in the MMR group and 10.5% in the vitamin D group).</p><p><strong>Conclusion: </strong>Both intralesional MMR vaccine and intralesional vitamin D are effective and safe immunotherapeutic options for the treatment of common warts. MMR vaccine may have a slight advantage over vitamin D in terms of complete response rate; however, further studies with larger sample sizes and longer follow-ups are needed to confirm this finding.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"70 3","pages":"169"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139626/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijd.ijd_890_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Common warts are benign skin lesions caused by human papillomavirus (HPV) infection. They are often resistant to conventional treatments and may cause cosmetic and psychological distress. Immunotherapy is a promising alternative that stimulates the host immune system to clear the virus and the infected cells. This study compared the efficacy and safety of two immunotherapeutic agents, intralesional measles, mumps, and rubella (MMR) vaccine and intralesional vitamin D, in the treatment of common warts.

Methods: This was a single-blind randomised controlled trial conducted at a tertiary care hospital in Kolkata, India. Patients aged 12 years or older with common warts were randomly assigned to receive either intralesional MMR vaccine or intralesional vitamin D every 3 weeks for a maximum of three doses or until complete resolution, whichever was earlier. The primary outcome was the reduction in the size of the largest wart. Secondary outcomes included patients' and physicians' global assessment, complete response rate, adverse effects, and recurrence rate.

Results: A total of 36 patients were enrolled and analysed. Both MMR and vitamin D groups showed a significant reduction in the size of the largest wart throughout the treatment period (P < 0.0001). There was no significant difference between the two groups in terms of size reduction, patients' and physicians' global assessment and adverse effects. The complete response rate was higher in the MMR group (64.7%) than in the vitamin D group (36.8%); however, the difference was not statistically significant (P = 0.14). The recurrence rate was low in both groups (5.9% in the MMR group and 10.5% in the vitamin D group).

Conclusion: Both intralesional MMR vaccine and intralesional vitamin D are effective and safe immunotherapeutic options for the treatment of common warts. MMR vaccine may have a slight advantage over vitamin D in terms of complete response rate; however, further studies with larger sample sizes and longer follow-ups are needed to confirm this finding.

一项比较局部注射维生素D和MMR(麻疹、腮腺炎、风疹)疫苗治疗疣的疗效的随机单盲对照试验。
简介:常见疣是由人乳头瘤病毒(HPV)感染引起的良性皮肤病变。它们通常对常规治疗有抵抗力,并可能导致美容和心理困扰。免疫疗法是一种很有前途的替代疗法,它可以刺激宿主免疫系统清除病毒和受感染的细胞。本研究比较了两种免疫治疗药物,疹内麻疹、腮腺炎和风疹(MMR)疫苗和疹内维生素D治疗常见疣的疗效和安全性。方法:这是一项在印度加尔各答一家三级保健医院进行的单盲随机对照试验。患有常见疣的12岁或以上的患者被随机分配每3周接受局灶内MMR疫苗或局灶内维生素D,最多3次,或直到完全消退,以较早者为准。主要结果是最大疣的大小减小。次要结局包括患者和医生的总体评估、完全缓解率、不良反应和复发率。结果:共纳入并分析了36例患者。在整个治疗期间,MMR组和维生素D组均显示最大疣的大小显著减少(P < 0.0001)。两组在缩小尺寸、患者和医生的总体评估和不良反应方面没有显著差异。MMR组的完全缓解率(64.7%)高于维生素D组(36.8%);但差异无统计学意义(P = 0.14)。两组复发率均较低(MMR组5.9%,维生素D组10.5%)。结论:瘤内MMR疫苗和瘤内维生素D是治疗常见疣有效、安全的免疫治疗选择。就完全缓解率而言,MMR疫苗可能比维生素D略有优势;然而,进一步的研究需要更大的样本量和更长时间的随访来证实这一发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Dermatology
Indian Journal of Dermatology Medicine-Dermatology
CiteScore
1.80
自引率
0.00%
发文量
217
审稿时长
47 weeks
期刊介绍: The journal publishes information related to skin-pathology and different modes of therapeutics, including dermatosurgery and cosmetic dermatology. Likewise, it carries articles on leprosy, STI and HIV/AIDS. The editorial board encourages the authors to publish articles addressing emerging techniques and developments in the subject specialty, in the form of Original investigations, Narrative and Systematic Reviews as well as Case Reports. The journal aims at publishing Editorials and Commentaries from eminent personalities on a regular basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信